The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya.

NCT05531552 | Completed DMC FDA Drug

• 1 other identifier: Clinical pharmacist role & ICU
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Assessment of role of clinical pharmacist in decreasing morbidity and mortality among coronary artery disease patients.

Conditions

Coronary Artery Disease

Keywords

clinical pharmacist role, ICU patients, CAD patients,

Outcome Measures

Primary Outcomes (4)

• Angina pectoris.

  Periodically data collected. \[ex: the measurements of blood pressure, glucose blood serum, and LDL - (and taken the average during the period)\]. The parameters in the research (angina, response to treatment, complication rate, and mortality) - were quantitatively collected, as the results added to the paper contain the number of patients with details of their complications or the cause of death of patients who died). The measuring of FBG level (mg/dl), and (LDL-C) mg/dl - was then performed using a fully automated chemistry analysis instrument by Roche company (Cobas Integra 400 plus). And using specific kits for blood glucose levels (System ID 07-6831-6) and using kits for (LDL-C) (System ID 07-6726-3), Troponin (ng\\ml) was performed by using (Beckman coulter - Access 2). Angina pectoris was more predominant in patients in group (I); vs. in group (II) with a statistically significant difference.

  18 months, from Jan 2021 to June 2022.

• Responsiveness to medications.

  Periodically data collected. \[ex: the measurements of blood pressure, diabetes, lipid profile, and weight - (and taken the average during the period)\]. The parameters in the research (angina, response to treatment, complication rate, and mortality) - were quantitatively collected, as the results added to the paper contain the number of patients with details of their complications or the cause of death of patients who died). Follow-up patients, their clinical state and side effects of medications, Following the number of Hospitalization decreased. Responsiveness to medications was significantly higher among patients from the group (II); compared with a control group (I)

  18 months, from Jan 2021 to June 2022.

• The incidence of complications.

  The complications are noticeable: myocardial infarctions \[Troponin was perpetrated by using by (Beckman coulter)(Access 2) ng\\ml\], cardiac arrhythmias \[by ECG\], cardiogenic shock \[after MI with HF and low BP\], HTN crisis {BP measure, DKA \[high blood glucose with (+) positive Ketones. Data were collected quantitatively, as the results added to the paper contain the number of patients with details of their complications).

  18 months, from Jan 2021 to June 2022.

• The mortality.

  The causes of death are cardiogenic shock, ventricular tachycardia, and myocardial infarction.

  18 months, from Jan 2021 to June 2022.

Study Arms (2)

Group I (control group)

was collect data without any interference (without clinical pharmacy guidelines). Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU.

Group II (observation group)

application of clinical pharmacy guidelines and management CAD. Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU.

Drug: clinical pharmacy application

Interventions

clinical pharmacy application DRUG

assessment clinical pharmacist in management of CAD and ICU patients.

Also known as: Follow-up patients and their drugs, to improve health and reduce morbidity and mortality.

Group II (observation group)

Eligibility Criteria

• Age: 41 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Follow-up one hundred patients, in two groups, divided each one into three subgroups {10-Outpatient, 25-Inpatient and 15 patients in Cardio Care Unit - CCU}. * The first group of patients was undergoing treatment in the (Medical Center Hospital) without applying clinical pharmacy guidelines. (10 patients-25pts.-15pts.). * The second group; are a group of patients undergoing treatment in the (Medical Center Hospital) in accordance with clinical pharmacy guidelines. (10pts.-25pts.-15pts.).

Sponsors & Collaborators

• Beni-Suef University: lead
• Medical Center Hospital, libya: collaborator
• Cairo University: collaborator

Study Sites (1)

Beni-suef university

Banī Suwayf, +20, Egypt

Location

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Mortality

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Intervention Hierarchy (Ancestors)

Vital Statistics; Data Collection; Epidemiologic Methods; Investigative Techniques; Demography; Population Characteristics; Epidemiologic Measurements; Public Health; Environment and Public Health

Study Officials

• Asmaa S. alhomri, BCH.PH

  Bachelor of Pharmaceutical Sciences, Faculty of Pharmacy, Omar Elmokhtar University, Tobruk, Libya.

  PRINCIPAL INVESTIGATOR

• Raghda S. Hussien, Lecturer

  Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni- Suef, Egypt.

  STUDY DIRECTOR

• Eman K. Abdelall, Professor

  Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni- Suef, Egypt.

  STUDY DIRECTOR

• Ahmed A. Battah, Professor

  Critical Care Department, Faculty of Medicine, Cairo University, Cairo, Egypt

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: BCH.PH & pharmaceutical science, Faculty of Pharmacy, Omar Elmokhtar University, Tobruk, Libya.

Study Record Dates

• First Submitted: August 30, 2022
• First Posted: September 8, 2022
• Study Start: January 1, 2021
• Primary Completion: June 30, 2022
• Study Completion: June 30, 2022
• Last Updated: July 27, 2023

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)